# The Medicines (Products for Human Use) (Fees) Regulations 2012, Paragraph 24: Marketing authorizations


(1) Unless paragraphs 25, 26, 28 or 29 apply, the fee payable under regulation 12(1)(a) in connection with an application for a marketing authorization of a kind described in column 1 of the following table is the fee specified in the corresponding entry in column 2 of that table.
Fees for marketing authorization applications
Column 1
Kind of application
Column 2
Fee payable
1. Major application
(a)
in respect of an application relating to an orphan medicinal product to which point 6 of Part 2 of Annex 1 to the 2001 Directive applies
£32,135
(b)
which is a mutual recognition procedure incoming application
£67,468
(c)
which is a European reference product application
£67,468
(d)
which is a decentralised procedure application where the United Kingdom is a concerned Member State
£96,797
(e)
which is a decentralised procedure application where the United Kingdom is a reference Member State
£139,235
(f)
in any other case
£100,252
2. Complex application
(a)
which is a mutual recognition procedure incoming application
£18,732
(b)
which is a European reference product application
£18,732
(c)
which is a decentralised procedure application where the United Kingdom is a concerned Member State
£26,762
(d)
which is a decentralised procedure application where the United Kingdom is a reference Member State
£40,780
(e)
in any other case
£27,716
3. Standard application
(a)
which is a mutual recognition procedure incoming application
£6,864
(b)
which is a European reference product application
£6,864
(c)
which is a decentralised procedure application where the United Kingdom is a concerned Member State
£9,812
(d)
which is a decentralised procedure application where the United Kingdom is a reference Member State
£17,920
(e)
in any other case
£10,162
4. Simple application
(a)
which is a decentralised procedure application where the United Kingdom is a concerned Member State
£2,771
(b)
which is a decentralised procedure application where the United Kingdom is a reference Member State
£9,275
(c)
in any other case
£2,771
5. Parallel import licence applications
(a)
in respect of a simple parallel import licence
£1,937
(b)
in respect of a standard parallel import licence
£7,201
(c)
in respect of a complex parallel import licence
£19,650
6. Change of ownership application
£478
(2) Each reference in paragraphs 25, 27 and 28 to an amount payable under paragraph 24 in respect of an application refers to the amount payable under that paragraph in respect of an application of the kind in question.

---
Source: https://www.legislation.gov.uk/nisr/2012/134/schedule/2/paragraph/24 (the official version)
Page: https://openlegislation.uk/medicines-products-for-human-use-fees-regulations-2012/schedule-2/paragraph-24
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.